Report

Update: Hungary Haematology offsets Chinese famine

Stratec, a German designer and builder of automated OEM diagnostic systems, has revised its core business guidance for 2016 and 2017 due to volatile client forecasts arising from sales uncertainty and local competition in China. Preliminary 2015 results showed revenues up 1.4% to €146.9m and an improved EBIT margin of 18.3% due to higher service part sales. The about €67m Diatron acquisition adds about €25m revenue in FY16 and €37m in FY17, taking our 2016 consolidated revenue forecast to a revised €176m, with 2017 revenues potentially at €198m. Diatron’s EBIT margin is assumed to be 17%, similar to Stratec’s core business.
Underlying
STRATEC SE

STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch